INTRODUCTION
============

Patients with non-valvular atrial fibrillation (AF) face an increased risk of stroke compared with those in normal sinus rhythm, though the magnitude of risk varies in relation to age and other clinical features \[[@R1],[@R2]\]. The vitamin K antagonist warfarin, available for over half a century, is highly effective in reducing the risk of stroke in patients with AF \[[@R3]\], but its use is complicated by variable dose-response due to genetic factors and multiple food and drug interactions, resulting in the need for frequent monitoring of anticoagulation intensity and frequent dose adjustments. As a result, it is challenging to keep the anticoagulant effect of warfarin in the desired range; the INR is in the optimum range of 2.0-3.0 about 50% of the time in most clinical settings. Newer oral anticoagulants (NOACs) that directly inhibit Factor IIa (thrombin) or Factor Xa provide reliable anticoagulation when administered in fixed oral doses without routine coagulation monitoring.

DIRECT THROMBIN INHIBITORS
==========================

Evaluation of the oral, direct thrombin inhibitor ximelagatran in the SPORTIF III and V trials \[[@R4]\] found it efficacious, but it was withdrawn from further development because of hepatotoxicity. Dabigatran, another oral Factor IIa inhibitor, was compared with warfarin in the RE-LY trial of 18,113 patients with AF at risk for stroke; patients were randomly assigned to one of two blinded doses of dabigatran etexilate, 110 mg or 150 mg twice daily, or open-label, dose-adjusted warfarin (target INR 2.0-3.0) \[[@R5],[@R6]\]. The mean CHADS~2~score of enrolled patients was 2.1, and the median duration of follow up was 2.0 years. The primary efficacy outcome was the rate of all stroke (ischemic or hemorrhagic) or systemic embolism. This occurred at rates of 1.71%/year in the group assigned to warfarin, 1.54%/year in those randomized to dabigatran, 110 mg b.i.d. (p\<0.001 for noninferiority to warfarin), and 1.11%/year with dabigatran, 150 mg b.i.d. (p\<0.001 for superiority to warfarin). Both doses of dabigatran were associated with significantly lower rates of hemorrhagic stroke (intracerebral hemorrhage) compared to warfarin. The higher dose yielded a rate of major bleeding similar to that with warfarin but a higher rate of gastrointestinal bleeding. All-cause mortality was lower with dabigatran (4.13%/year for warfarin, 3.75%/year for dabigatran, 110 mg bid, 3.64%/year for dabigatran, 150 mg bid), but did not reach statistical significance (p=0.13 and p=0.051 for the 110 mg and 150 mg bid doses, respectively). These findings led to regulatory approval of dabigatran etexilate at the 150 mg twice daily dose to reduce the risk of stroke and systemic embolism in patients with nonvalvular AF in the U.S., Canada, Europe and many other countries as the first novel anticoagulant for this indication. Unlike regulators in most other countries, the U.S Food and Drug Administration did not approve the lower 110 mg b.i.d. dose formulation. Although patients with severe renal impairment (creatinine clearance Cr~Cl~ [≤]{.ul}30 mL/min) were excluded from RE-LY, the FDA approved an even lower dose of 75 mg twice daily for patients with Cr~Cl~ 15-30 mL/min, based on pharmacokinetic modeling, despite a lack of clinical data \[[@R7]\]. Dabigatran has been approved in Canada and Europe for prevention of venous thromboembolism (VTE) in patients undergoing total hip or knee replacement surgery and in the U.S. for treatment of patients with VTE and prevention of recurrence.

DIRECT FACTOR XA INHIBITORS
===========================

In the ROCKET AF trial, the oral direct Factor Xa inhibitor, rivaroxaban, proved noninferior to warfarin for prevention of stroke or systemic embolism and resulted in significantly fewer fatal bleeding events and hemorrhagic stroke \[[@R8]\]. The trial included 14, 264 patients with AF at generally higher risk of stroke than those enrolled in the RE-LY study (mean CHADS~2~score = 3.5). More than half of the enrolled patients (55%) had sustained previous stroke, systemic embolism or transient ischemic attack (TIA). Patients were randomized to receive dose-adjusted warfarin (goal INR 2.0-3.0) or fixed-dose rivaroxaban, 20 mg once daily (15 mg daily for those with Cr~Cl~ 30-49 ml/min) double-blind. Over a median follow-up period of 707 days, the primary efficacy endpoint was reached in 188 patients with rivaroxaban group and in 241 with warfarin group (1.7 and 2.2 per 100 patient-years, respectively; p\<0.001 for noninferiority) in the per-protocol on-treatment population. When analyzed by intention-to-treat (ITT), the primary event rates were 2.1 per 100 patient-years in the warfarin group and 2.4 per 100 patient-years in the rivaroxaban group, meeting the criterion for noninferiority (p\<0.001) but not superiority (p=0.12). There was an accumulation of events when those randomized to rivaroxaban were transitioned to open-label warfarin at the end of the study treatment period and anticoagulation intensity may have been below the therapeutic range for nearly two weeks.

There was no difference in the rate of major and clinically relevant non-major bleeding (14.5 vs. 14.9 per 100 patient-years in the warfarin and rivaroxaban groups, respectively; p=0.44). Patients randomized to rivaroxaban experienced more gastrointestinal bleeding, more often developed declines in hemoglobin concentration of 2 g/dL and more often required blood transfusion than those in the warfarin group, but there were significantly lower rates of hemorrhagic stroke (0.5 vs 0.7 per 100 patient-years, p=0.02) and fatal bleeding (0.2 vs 0.5%, p=0.003) with rivaroxaban compared with warfarin. The difference in all-cause mortality (1.9 and 2.2 per 100 patient-years, p=0.073) with rivaroxaban compared with warfarin, respectively, did not satisfy criteria for statistical significance. Rivaroxaban has been approved by the FDA, Canadian and European health authorities to reduce the risk of stroke and systemic embolism in patients with non-valvular AF and in different dosing regimens for prevention of VTE in patients undergoing major orthopedic surgery of the hip or knee and for treatment of deep venous thrombosis and/or pulmonary embolism.

Another Factor Xa inhibitor, apixaban, was evaluated in the ARISTOTLE trial \[[@R9]\], in which 18,201 patients with non-valvular AF and at least one additional risk factor for stroke (mean CHADS~2~ score 2.1) were randomized to apixaban, 5 mg b.i.d. (2.5 mg b.i.d. for those with two or more of the following factors associated with increased drug exposure: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL) or dose-adjusted warfarin (target INR 2.0-3.0). A total of 19% of patients had a previous TIA, stroke, or systemic embolism. The mean follow-up was 1.8 years. The primary efficacy outcome (stroke or systemic embolism) occurred less often in the apixaban group (1.27%/year) than in the warfarin group (1.60%/year; p\<0.001 for noninferiority; p=0.01 for superiority). The apixaban group also exhibited lower rates of hemorrhagic stroke (0.24 vs. 0.47%/year; p=\<0.001), major bleeding (2.13 vs. 3.09%/year; p\<0.001), intracranial hemorrhage (0.33 vs. 0.80% per year; p\<0.001) and all-cause mortality (3.52 vs. 3.94%/year; p=0.047). There were small and statistically insignificant reductions in rates of major gastrointestinal bleeding, myocardial infarction (MI) and death from cardiovascular causes.

A separate large clinical trial, AVERROES, compared apixaban to aspirin for prevention of stroke and systemic embolism in 5,599 patients with AF for whom VKA therapy was deemed unsuitable \[[@R10]\]. The trial was terminated prematurely when apixaban showed convincingly superior efficacy in reducing the risk of stroke or systemic embolism without increases in the risk of major bleeding or hemorrhagic stroke. Based on the results of the ARISTOTLE and AVERROES trials, apixaban has been approved in the U.S. and in Europe for prevention of VTE in patients undergoing major orthopedic surgery of the hip or knee and for stroke prevention in patients with AF in Europe, Canada and the U.S.

Two doses of the direct Factor Xa inhibitor, edoxaban, 30 and 60 mg once daily, in comparison to warfarin for prevention of stroke in patients with AF were investigated in the ENGAGE AF-TIMI 48 trial of 21,105 patients \[[@R11]\]. Results were reported in 2013, and the drug is currently undergoing regulatory review.

CRITICAL ASSESSMENT AND COMPARISON OF THE TRIAL RESULTS
=======================================================

Assessment of the completed trials comparing the FDA-approved new oral anticoagulants ("NOACs") with warfarin reveals several similarities and differences (Fig. **[1](#F1){ref-type="fig"}**). Dabigatran, rivaroxaban and apixaban are all noninferior to warfarin for prevention of stroke and systemic embolism in patients with AF, and each of these agents significantly reduced the rate of hemorrhagic stroke. In an ITT analysis, dabigatran 150 mg b.i.d. and apixaban significantly reduced the rate of all cause stroke. Only dabigatran, 150 mg b.i.d. was statistically superior to warfarin for prevention of ischemic stroke. All were noninferior to warfarin with respect to avoidance of major bleeding, and apixaban and dabigatran, 110 mg b.i.d., reduced major bleeding. All 3 drugs led to a 9-12% reduction in all-cause mortality, although this finding was significant only for apixaban. All trials reported reductions in fatal or life-threatening bleeding compared with warfarin. Rivaroxaban and dabigatran, 150 mg b.i.d., increased gastrointestinal hemorrhage but this was not observed with apixaban or the lower dose of dabigatran, 110 mg b.i.d. Since trials directly comparing one NOAC with another have not been conducted, and there are important differences in patient populations, study designs and methodological factors, we cannot draw conclusions about the relative safety or efficacy of the individual drugs or classes (Factor IIa and Factor Xa inhibitors) based on data currently available. The lack of comparative effectiveness data creates a challenge to practitioners, but the collective data make it clear that, considered as a group with respect to safety and efficacy, the NOACs offer favorable net clinical benefit compared to warfarin for many patients with AF.

MYOCARDIAL INFARCTION
=====================

There was no significant difference in rates of MI between the NOACs and warfarin in the contemporary trials. In trials of dabigatran, however, there was a trend -- not statistically significant -- of higher rates of MI than observed in patients treated with warfarin \[[@R6],[@R12]\]. Meta-analysis of seven randomized trials suggested that dabigatran might be associated with an increased risk of MI, but the bulk of the experience was derived from the RE-LY trial. In most studies on patients with AF, rates of MI are considerably lower than those of stroke, and the risk of subsequent MI was not increased in those with coronary disease of prior MI treated with dabigatran relative to warfarin in RE-LY or in a subsequent analysis of post-marketing experience among Medicare enrollees in the U.S. conducted by the FDA \[[@R6],[@R12], 12a\].

No dosing recommendations can be made based on currently available evidence for use of the NOACs in patients with AF who are receiving dual antiplatelet therapy (DAPT) following acute coronary syndrome (ACS) \[[@R13]-[@R15]\] or percutaneous coronary intervention (PCI). Anticoagulated patients treated concurrently with platelet inhibitor drugs face a significantly higher risk of bleeding than those receiving either type of antithrombotic agent alone, and among anticoagulated patients with AF in the RE-LY trial, antiplatelet therapy was the most important independent, modifiable risk factor for hemorrhagic stroke \[[@R16]\].

SECONDARY PREVENTION
====================

Patients with AF who have suffered previous stroke or TIA face a risk of recurrent stroke approximately 2.5 times greater than those without prior events \[[@R17]\] and are also at greater risk of bleeding \[[@R18]\]. In the subgroup of 3,623 patients with previous stroke or TIA randomized in the RE-LY trial, rates of stroke or systemic embolism were 2.78%/year in the warfarin group, compared with 2.32%/year with dabigatran, 110 mg b.i.d. (relative risk \[RR\] 0.84, 95% confidence interval \[CI\] 0.58-1.20), and 2.07%/year) with dabigatran, 150 mg b.i.d. (RR 0.75; 95% CI 0.52-1.08). The rate of major bleeding was significantly lower in patients with dabigatran, 110 mg b.i.d. (RR 0.66, 95% CI 0.48-0.90) but similar in patients randomized to 150 mg b.i.d. (RR 1.01; 95% CI 0.77-1.34) compared to warfarin. The effects of dabigatran in patients with previous stroke or TIA and did not differ from those in patients without prior thromboembolic events for any of the outcomes in the RE-LY trial other than vascular death, which was lower in the 110 mg b.i.d. group compared with warfarin group (interaction p=0.038) \[[@R19]\].

In the ARISTOTLE and RE-LY trials, 19 and 20%, respectively, had experienced previous stroke or TIA. In the ROCKET AF trial, 52 percent of enrolled patients had prior cerebral ischemic events (excluding systemic embolism outside the central nervous system). While the absolute event rates were generally higher in those with prior stroke or TIA, there was no significant difference in relative efficacy or safety of rivaroxaban compared with warfarin in this population compared with those in the entire ROCKET AF trial population. The event rate for the primary endpoint with rivaroxaban (2.79 per 100 patient-years) compared with warfarin (2.96 per 100 patient-years) was consistent in patients with previous stroke or TIA (hazard ratio \[HR\] 0.94, 95% CI 0.77--1.16) and those without (1.44 *vs*1.88%/100 patient-years; HR 0.77, 95% 0.58--1.01; interaction p=0.08) \[[@R20]\]. Rates of major and non-major clinically relevant bleeding per 100 person-years were also consistent among patients with previous stroke or TIA (13.31/100 patient-years on rivaroxaban *vs*13.87/100 patient-years on warfarin; HR 0.96, 95% CI 0.87--1.07) and those without (16.69 *vs*15.19/100 patient-years; HR 1.10, 95% CI 0.99--1.21; interaction p=0.08).

In the secondary prevention subgroup of the ARISTOTLE trial, the rate of stroke or systemic embolism was 2.46/100 patient-years in the apixaban group and 3.24 in the warfarin group (HR 0.76, 95% CI 0.56-1.03); in those without previous stroke or TIA, the rate of stroke or systemic embolism was 1.01/100 patient-years with apixaban and 1.23 with warfarin (HR 0.82, 95% CI 0.65-1.03; interaction p=0.71). The absolute reduction in the rate of stroke and systemic embolism with apixaban *vs* warfarin was 0.77/100 patient-years (95% CI -0.08-1.63) in patients with and 0.22 (-0.03 to 0.47) in those without previous stroke or TIA. The absolute reduction in major bleeding with apixaban compared with warfarin was 1.07/100 patient-years (95% CI 0.09-2.04) in patients with and 0.93 (0.54-1.32) in those without previous stroke or TIA \[[@R21]\].

Individually, each of these subgroup analyses was underpowered to demonstrate with statistical confidence the noninferiority or superiority of the NOACs compared to warfarin for secondary prevention of ischemic events in patients with AF who had experienced prior stroke or TIA, nor can conclusions be drawn about the performance of one of the novel agents vs. another. Meta-analysis of the 14, 527 patients with prior stroke or TIA randomized in the three pivotal trials found the NOACs associated with a significant reduction of stroke and systemic embolism (odds ratios \[OR\] 0.85, 95% CI 074-0.99\]; relative RR 14%; absolute RR, 0.7%; number needed-to-treat \[NNT\], 134 over 1.8-2.0 years) compared with warfarin. The NOACs were also associated with a significant reduction in major bleeding compared with warfarin (OR 0.86, 95% CI 075-0.99; relative RR 13%; absolute RR 0.8%; NNT 125), driven mainly by the significant reduction of hemorrhagic stroke (OR 0.44, 95% CI 032-0.62; relative RR 57.9%; absolute RR 0.7%; NNT 139). Hence, preservation of their relative efficacy and safety and conformity with the overall trial results supports the use of the NOACs as alternatives to warfarin for secondary prevention of recurrent as well as primary prevention of first stroke in patients with AF \[[@R29]\].

RENAL IMPAIRMENT
================

Patients with AF and renal dysfunction are at increased risk of both ischemic and bleeding events \[[@R22]-[@R24]\]. Warfarin treatment reduces the risk of stroke or systemic embolism in patients with chronic kidney disease, but warfarin and aspirin are associated with increased risks of bleeding. In the RE-LY trial, the risk of major bleeding with dabigatran or warfarin was a \>2-fold higher in patients with a Cr~Cl~\<50 mL/min compared with those with clearance ≥80 mL/min., but the relative increase in bleeding risk was similar for both drugs \[[@R25]\] Dabigatran is approximately 80% excreted via the renal route, and higher concentrations of the drug accumulate in the blood of patients with renal dysfunction \[[@R26]\]. Dabigatran is contraindicated in patients with estimated Cr~Cl~ \<30 mL/min in Europe and Canada, and the 75 mg b.i.d. dose is approved for use in patients with Cr~Cl~15-29 ml/min in the US.

In ROCKET AF, 20.7% of the trial cohort had moderate renal impairment (Cr~Cl~ 30-49 mL/min). Patients with moderate renal impairment were given a reduced dose of rivaroxaban (15 mg once daily). Results of a pre-specified secondary analysis of patients with renal impairment were consistent with the overall trial results \[[@R27]\]. Among those with Cr~Cl~ 30--49 mL/min, the primary endpoint of stroke or systemic embolism occurred in 2.32 per 100 patient-years with rivaroxaban 15 mg/day vs. 2.77 per 100 patient-years with warfarin (HR 0.84; 95% CI 0.57--1.23) in the per-protocol population. Intention-to-treat analysis yielded similar results (HR 0.86; 95% CI 0.63--1.17). Rates of major and clinically relevant non-major bleeding (17.82 vs. 18.28/100 patient-years; p=0.76) and hemorrhagic stroke (0.71 vs. 0.88/100 patient-years, p=0.54) were similar with rivaroxaban or warfarin. Fatal bleeding (0.28 vs. 0.74/100 patient-years, p=0.047) occurred less often with rivaroxaban. Since clinical data are limited, rivaroxaban should be used with caution in patients with severe renal impairment (Cr~Cl~\<30 ml/min and in those with renal impairment concomitantly receiving other drugs that increase the plasma concentration of rivaroxaban. Similarly to observations with rivaroxaban and dabigatran, the subgroup of patients with renal impairment in the ARISTOTLE trial tracked the main study results; the hazard ratio for bleeding was even lower when the GFR was low \[[@R28]\]. Although the U.S. FDA has allowed labeling of apixaban for patients with end-stage renal disease receiving hemodialysis, clinical data on safety and efficacy in this population are lacking.

PATIENT AGE
===========

The risk of bleeding among patients randomized in the RE-LY trial increased with age, and compared with warfarin both doses of dabigatran were associated with an increasing relative risk of major bleeding with increasing age categories (\<65, 65 to 74, ≥75 years; interaction p\<0.001 for each analysis) \[[@R25]\]. Compared with warfarin, dabigatran 110 mg b.i.d. was associated with a lower risk of major bleeding (2.87 vs 3.57%; *p=*0.002), whereas dabigatran 150 mg b.i.d. was associated with a similar risk of major bleeding (3.31 vs 3.57%; *p=*0.32). There was a significant treatment-by-age interaction, such that dabigatran 110 mg b.i.d. was associated with a lower risk of major bleeding in patients aged \<75 years old (1.89% vs 3.04%; *P\<*0.001) and a similar risk in those ≥75 years old (4.43 versus 4.37%; *p=*0.89; interaction p\<0.001), whereas dabigatran 150 mg b.i.d. was associated with a lower risk of major bleeding in those aged \<75 years (2.12 vs 3.04%; *p\<*0.001) and a trend toward higher risk of major bleeding in those ≥75 years old (5.10 vs 4.37%; *p=*0.07; interaction p\<0.001). The interaction with age was evident for extracranial bleeding, but not for intracranial bleeding, with the risk of the latter consistently reduced with dabigatran compared with warfarin in patients of all ages. There was no significant interaction between treatment and Cr~Cl~ for major bleeding, suggesting that other age-related factors are more important than renal function in determining bleeding risk in elderly patients treated with dabigatran. Higher blood concentrations of dabigatran with increasing age might contribute to the higher risk of extracranial bleeding with dabigatran compared with warfarin in elderly patients.

Data regarding age-related bleeding in the ROCKET AF trial of rivaroxaban are available only in preliminary form \[[@R30]\]. Compared to younger patients, those ≥75 years old at entry had a mean CHADS~2~ score of 3.7 vs. 3.3, and a higher proportion were female (46 vs. 35%). During 9,247 patient-years exposure, 429 stroke or systemic embolic events occurred among patients ≥75 years old. The on-treatment thromboembolism rates of 1.78 vs. 2.65 per 100 patient-years with rivaroxaban and warfarin, respectively (HR 0.67; 95% CI 0.51--0.89) were not much higher than in younger patients. By intention-to-treat analysis, rates of stroke and systemic embolism were 2.29 vs 2.85 per 100 patient-years among older patients treated with rivaroxaban vs warfarin, respectively (HR 0.80; 95% CI 0.63-1.02), compared with 2.00 vs 2.10 per 100 patient-years among those under age 75 years (HR 0.95; 95% CI 0.76-1.19; interaction *p=*0.3131 for differences in treatment effect related to age). Older patients had higher rates of (mostly non-major) clinically relevant bleeding (interaction *p*=0.009), but rates with warfarin and rivaroxaban were comparable. Hence, among the relatively high-risk elderly patients enrolled in ROCKET AF, rivaroxaban performed favorably compared to adjusted-dose warfarin, as it did in the overall ROCKET-AF population. A subgroup analysis of the response of elderly patients to apixaban in the ARISTOTLE trial found greater absolute benefit of apixaban in the elderly due to the higher risk associated with age. Apixaban was more effective than warfarin in preventing stroke, reducing mortality and associated with less major bleeding, total bleeding, and intracranial hemorrhage regardless of age (interaction p\>0.11 for all analyses) \[30a\].

OTHER PERTINENT CLINICAL SUBGROUPS
==================================

Subgroup analyses of other clinically important subgroups of patients with AF in trials comparing the NOACs with warfarin have been reported, including those stratified by center-based quality of warfarin anticoagulation control (time in therapeutic range \[TTR\]). In the RE-LY trial, the benefits of dabigatran, 150 mg b.i.d. at reducing stroke, the 110 mg b.i.d. dose at reducing bleeding, and both doses at reducing hemorrhagic stroke were consistent irrespective of the quality of INR control, though in terms of all ischemic events and mortality, the advantages of dabigatran were greater at sites with poor INR control than at those with good INR control \[[@R31]\]. Since the quality of anticoagulation management generally parallels other aspects of health care quality, rates of adverse clinical events, including stroke and bleeding are typically lower at clinical centers where higher TTR values are achieved. While patients receiving well-controlled warfarin therapy may gain less advantage from substitution of one of the NOACs in terms of efficacy, the subgroup analyses are typically under-powered to support firm conclusions, and there is little evidence that the lower rates of hemorrhagic stroke during NOAC therapy are related to the TTR of the warfarin comparator \[31a\].

Studies of other subgroups, including patients classified as naïve to warfarin prior to randomization, those with diabetes mellitus or heart failure, and those delineated by ethnicity or geographical region, have generally been consistent with the main trial results (interaction p-values for these variables not significant). These secondary analyses must be considered exploratory, however, and additional studies will be needed in independently selected cohorts, to identify specific patient characteristics associated with greater or lesser efficacy or efficacy of the NOACs when used for stroke prevention.

CONCLUSIONS
===========

The NOACs studied in phase III clinical trials completed to date have displayed generally favorable efficacy and safety profiles compared to warfarin. For patients on stable, long-term doses of warfarin, the advantage of substituting one of these new agents is less well established, and additional data on cost-effectiveness and safety during longer periods of exposure may inform prescribing practice. In patients with poorly controlled INR values in follow-up, or with new therapy initiation, the potential advantages of the NOACS are likely to be most manifest. Although comparisons of one NOAC another is complicated by differences in patient population, study design and other methodological factors \[[@R32]\], all represent viable alternatives to warfarin for stroke prevention in patients with nonvalvular AF.
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